High-dose therapy. Experience of the non-Hodgkin’s lymphoma
Co-operative Study Group (NHLCSG)
G. Santini for the NHLCSG
Department of Haematology, San Martino Hospital, Genoa, Italy
In aggressive, advanced stage non-Hodgkin’s lymphoma (NHL), 2nd and 3rd generation regimens gave results similar to those observed with CHOP therapy with a CR of approximately 50%, a 3-year survival probability of approximately 50% and a PFS of 35-40%. In order to improve outcome of these patients we started the 1st our study on the use of high-dose therapy as front-line therapy.